- Home
- BIIB vs CELH Comparison
BIIB vs CELH Comparison
Compare BIIB & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CELH
- Stock Information
- Founded
- BIIB 1978
- CELH 2004
- Country
- BIIB United States
- CELH United States
- Employees
- BIIB N/A
- CELH N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- BIIB Health Care
- CELH Consumer Staples
- Exchange
- BIIB Nasdaq
- CELH Nasdaq
- Market Cap
- BIIB 18.7B
- CELH 16.6B
- IPO Year
- BIIB 1991
- CELH N/A
- Fundamental
- Price
- BIIB $154.27
- CELH $60.23
- Analyst Decision
- BIIB Buy
- CELH Strong Buy
- Analyst Count
- BIIB 22
- CELH 18
- Target Price
- BIIB $174.11
- CELH $64.06
- AVG Volume (30 Days)
- BIIB 1.5M
- CELH 3.8M
- Earning Date
- BIIB 10-30-2025
- CELH 11-06-2025
- Dividend Yield
- BIIB N/A
- CELH N/A
- EPS Growth
- BIIB N/A
- CELH N/A
- EPS
- BIIB 10.97
- CELH 0.39
- Revenue
- BIIB $10,065,900,000.00
- CELH $1,666,480,000.00
- Revenue This Year
- BIIB $2.03
- CELH $84.78
- Revenue Next Year
- BIIB N/A
- CELH $30.62
- P/E Ratio
- BIIB $14.06
- CELH $152.60
- Revenue Growth
- BIIB 4.77
- CELH 11.85
- 52 Week Low
- BIIB $110.04
- CELH $21.10
- 52 Week High
- BIIB $179.48
- CELH $66.74
- Technical
- Relative Strength Index (RSI)
- BIIB 64.58
- CELH 48.38
- Support Level
- BIIB $138.00
- CELH $60.00
- Resistance Level
- BIIB $151.91
- CELH $62.55
- Average True Range (ATR)
- BIIB 4.62
- CELH 2.17
- MACD
- BIIB 0.21
- CELH -0.56
- Stochastic Oscillator
- BIIB 94.70
- CELH 14.23
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.